Minocycline

Generic Name
Minocycline
Brand Names
Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi
Drug Type
Small Molecule
Chemical Formula
C23H27N3O7
CAS Number
10118-90-8
Unique Ingredient Identifier
FYY3R43WGO
Background

Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
...

Indication

Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumo...

Associated Conditions
Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions
Associated Therapies
-
Clinical Trials
Related News

Minocycline As Adjunctive Treatment for Treatment Resistant Depression

Phase 3
Active, not recruiting
Conditions
Treatment Resistant Depression
Interventions
Drug: Minocycline
First Posted Date
2019-05-13
Last Posted Date
2024-11-14
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
76
Registration Number
NCT03947827
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

The Effect of Acute Minocycline Administration on Emotional Processing and Cognition in Healthy Volunteers

Not Applicable
Completed
Conditions
Cognitive Change
Mood
Interventions
Other: placebo
Drug: Minocycline
First Posted Date
2018-12-07
Last Posted Date
2019-04-18
Lead Sponsor
University of Oxford
Target Recruit Count
40
Registration Number
NCT03768557
Locations
🇬🇧

Warneford Hospital, Oxford, Oxfordshire, United Kingdom

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

First Posted Date
2018-04-05
Last Posted Date
2024-04-09
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
42
Registration Number
NCT03489629
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States

🇺🇸

University of Washington Medical Center and Seattle Children's, Seattle, Washington, United States

and more 6 locations

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

First Posted Date
2018-01-30
Last Posted Date
2024-06-24
Lead Sponsor
University of Nebraska
Target Recruit Count
400
Registration Number
NCT03414502
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Minocycline Pharmacokinetics (ACUMIN)

Phase 4
Completed
Conditions
Bacterial Infection
Interventions
Drug: Minocycline
First Posted Date
2017-12-12
Last Posted Date
2020-12-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
58
Registration Number
NCT03369951
Locations
🇺🇸

Northwestern Memorial Hospital - ICU, Chicago, Illinois, United States

🇺🇸

University of Louisville School of Medicine - Surgery, Louisville, Kentucky, United States

🇺🇸

Washington University School of Medicine in St. Louis - Infectious Diseases, Saint Louis, Missouri, United States

and more 12 locations

Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans

Phase 4
Completed
Conditions
PTSD
Interventions
Drug: Minocycline
First Posted Date
2017-11-13
Last Posted Date
2020-07-09
Lead Sponsor
Sriram Ramaswamy
Target Recruit Count
10
Registration Number
NCT03340350
Locations
🇺🇸

VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, United States

Neuroprotection in Acute Ischemic Stroke

First Posted Date
2017-10-24
Last Posted Date
2023-12-19
Lead Sponsor
Stony Brook University
Target Recruit Count
15
Registration Number
NCT03320018
Locations
🇺🇸

Stony Brook University Hospital, Stony Brook, New York, United States

Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV

Phase 1
Withdrawn
Conditions
Normal Healthy Volunteers
Interventions
Drug: Minocycline
First Posted Date
2017-09-25
Last Posted Date
2023-09-21
Lead Sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Registration Number
NCT03291158
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Minocycline for Alcohol Use Disorder

First Posted Date
2017-08-09
Last Posted Date
2019-01-24
Lead Sponsor
University of California, Los Angeles
Registration Number
NCT03244592

Measuring Brain Inflammation in Autism

Phase 1
Suspended
Conditions
Autism Spectrum Disorder
Interventions
Drug: Minocycline
First Posted Date
2017-04-18
Last Posted Date
2020-08-10
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
30
Registration Number
NCT03117530
Locations
🇺🇸

UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy